GIM
BIIB icon

Glenmede Investment Management’s Biogen BIIB Stock Holding History

Glenmede Investment Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$3.63M Sell
25,891
-449
-2% -$60.7K 0.02% 485
2025
Q2 		$3.31M Buy
+26,340
New +$3.28M 0.02% 498

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Glenmede Investment Management's BIIB Position: Q3 2025 in Review

Glenmede Investment Management reduced its Biogen (BIIB) stake by 1.7% in Q3 2025, selling an estimated $60.7K and leaving 25,891 shares worth $3.63M. The position accounts for 0.02% of the portfolio, ranked #485.

Glenmede Investment Management first reported a position in BIIB in Q2 2025 and has held it in 2 quarters since. 905 funds tracked by Wall St. Rank hold BIIB as of Q3 2025.

  • Glenmede Investment Management held 25,891 shares of Biogen worth $3.63M as of Q3 2025.
  • Glenmede Investment Management sold 449 Biogen shares in Q3 2025, an estimated $60.7K.
  • Biogen made up 0.02% of Glenmede Investment Management's portfolio in Q3 2025, its #485 holding.
  • Glenmede Investment Management first reported a position in Biogen in Q2 2025 and has held it in 2 quarters since.
  • 905 funds tracked by Wall St. Rank held Biogen as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.